Abstract:Objective This study investigated the application value of ultrasound combined with thioredoxin reductase detection for the detection of breast malignant lesions in BI-RADS category 3 nodules (≤2?cm). Methods Physical examiners with ultrasound BI-RADS category 3 nodules (≤2?cm) treated in affiliated Dongfeng Hospital from Jan. 2015 to Jan. 2016, including 102 cases underwent breast ultrasound combined with thioredoxin reductase detection (observation group) and 110 cases underwent breast ultrasound only (control group) were collected. All 212 cases were diagnosed by pathological examination to compare the clinical characteristics and the detection rate of malignant lesions between two groups. Results There were no significant difference between two groups in menstrual condition, age of menarche and biopsy methods (all P?>?0.05). The positive rate of thioredoxin reductase detection is positively correlated with the positive rate of pathology for BI-RADS category 3 nodules in observed group. The rate of benign lesions between observed group (92.4%) and control group (93.5%) was no significant difference (P?>?0.05). The rate of malignant lesions in observed group (8.9%) was obviously higher than the control group (1.8%) (P?0.05). Conclusion The breast ultrasound BI-RADS category 3 nodules (≤ 2 cm) combined with thioredoxin reductase detection is valuable for improving the positive rate of malignant lesions in BI-RADS category 3 breast nodules, which is worthy of clinical application.